<DOC>
	<DOCNO>NCT00042835</DOCNO>
	<brief_summary>Erlotinib may stop growth tumor cell block enzymes necessary growth . Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining erlotinib radiation therapy combination chemotherapy may kill tumor cell . Phase I trial study effectiveness combine erlotinib radiation therapy combination chemotherapy treat patient inoperable stage III non-small cell lung cancer</brief_summary>
	<brief_title>Erlotinib Radiation Therapy Plus Combination Chemotherapy Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose erlotinib administer chest radiotherapy combination cisplatin etoposide carboplatin paclitaxel patient inoperable stage III non-small cell lung cancer . II . Determine dose-limiting toxicity regimens patient . III . Assess clinical response ( complete response , partial response , progressive disease , stable disease ) patient treat regimen . IV . Determine level tumor epidermal growth factor expression patient treat regimen . OUTLINE : This multicenter , dose-escalation study erlotinib . Patients assign 1 2 treatment group . GROUP 1 : Patients receive cisplatin IV 2 hour day 1 , 8 , 29 , 36 ; etoposide IV 1 hour day 1-5 29-33 ; oral erlotinib daily day 1-49 . Patients undergo concurrent radiotherapy 5 day week 7 week begin day 1 . Patients receive consolidation therapy comprise docetaxel IV 1 hour day 50 , 71 , 92 . Some patient may also receive oral erlotinib daily day 50-112 . GROUP 2 : Patients receive induction chemotherapy comprise paclitaxel IV 1 hour carboplatin IV 30 minute day 1 21 . Patients receive consolidation therapy comprise paclitaxel IV 1 hour carboplatin IV 30 minute day 43 , 50 , 57 , 64 , 71 , 78 , 85 oral erlotinib daily day 43-91 . Patients undergo radiotherapy concurrently consolidation therapy 5 day week 7 week begin day 43 . In group , cohort 3-6 patient receive escalate dos erlotinib concurrent chemoradiotherapy maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose-limiting toxicity . At least 12 patient group treat MTD . Patients follow 8 week . PROJECTED ACCRUAL : A total 24-48 patient ( 12-24 per treatment group ) accrue study within 6-12 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Adenocarcinoma , Bronchiolo-Alveolar</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically confirm nonsmall cell lung cancer Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar ) Large cell carcinoma ( include giant clear cell carcinoma ) Stage IIIA ( T1 T2 , N2 ) IIIB disease amenable resection surgery T3 , N2 T4 , N0N2 disease also allow base closeness carina , invasion mediastinum , invasion chest wall T3 , N0N1 disease allow provided disease amenable surgical resection No M1 disease No disease invasion vertebral body Tumors adjacent vertebral body allow provided gross disease encompass radiotherapy boost field bone invasion Contralateral mediastinal disease ( N3 ) allow gross disease encompass radiotherapy boost field Pleural effusion transudative , cytologically negative , nonbloody allow tumor encompass reasonable field radiotherapy No exudative , bloody , cytologically malignant effusion Effusions present CT scan chest xray ( CXR ) small thoracentesis allow Measurable evaluable disease Pleural effusion consider measurable evaluable Measurable disease define mass 2 perpendicular diameter CXR , CT scan , MRI Evaluable disease include lesion apparent CXR CT scan : Illdefined mass associate postobstructive change Mediastinal hilar adenopathy measurable one dimension Performance status ECOG 01 Performance status Karnofsky 70100 % More 6 month WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST ALT great 1.5 time upper limit normal ( ULN ) alkaline phosphatase normal AST ALT normal alkaline phosphatase great 2.5 time ULN Creatinine normal Creatinine clearance least 50 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No history cornea abnormality ( e.g. , dryeye syndrome , Sj√∂gren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein , BengalRose ) No abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) No gastrointestinal tract disease result inability take oral medication No required IV alimentation No peptic ulcer disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergy compound similar chemical biologic composition erlotinib study agents No significant traumatic injury within past 21 day No uncontrolled concurrent illness No ongoing active infection No psychiatric illness social situation would preclude study compliance No active malignancy within past 6 month except nonmelanoma skin cancer No concurrent colonystimulating factor ( filgrastim [ GCSF ] sargramostim [ GMCSF ] ) radiotherapy No prior chemotherapy lung cancer See Disease Characteristics No prior chest radiotherapy See Disease Characteristics At least 7 day since prior mediastinoscopy More 3 week since prior formal exploratory thoracotomy More 3 week since prior major surgery No prior surgical procedure affect absorption No prior epidermal growth factor receptortargeting therapy No concurrent investigational commercial agent therapy direct malignancy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>